Kornimate/medical-research-clean huggingface dataset:
pain relief after high thoracic eretor spinae block

Conditions: Pain, Chronic

Summary: the primary endpoint of this study was to identify if the espb in the patients of cervical radiculopathy has the effect of pain relief. the secondary endpoint of this study was to identify the spread level in the craniocaudal direction when performed at the t2 level.

the espb requires ultrasound guidance which enables visible local anesthetic spread underneath the erector spinae muscles. the spinalis, longissimus thoracis, and iliocostalis muscles comprise the es muscles, which run vertically along both sides of the vertebral column from the sacrum up to the skull base (1,10). the espb can be performed in the cervical, thoracic, and lumbar regions. among them, upper or mid thoracic espb has been used more widely compared to cervical and lumbar regions. previous cadaveric studies on the espb at the t5 level using computed tomography (ct) reconstruction or direct dissection demonstrated the extensive craniocaudal distribution of methylene blue ranging from t1 to t8 vertebral segments deep to the es muscles and variable involvement of epidural, paravertebral, and intercostal spaces. the espb performed at the t2 level of the cadaver demonstrated an injected dye distribution ranging from c4 to t10. also, 36% of cadavers showed the spread of an injected dye to the ventral, dorsal ramus, paravertebral space, and even the contralateral side. the exact mechanism of action of espb remains unclear. a recent study suggested that the analgesic effect of espb could be obtained by blocking the ventral and dorsal ramus of the spinal nerves by passing through the costotransverse foramen. however, in clinical practice, we can encounter highly variable clinical outcomes or sensory block after the espb. the study of the physical spread of the injected agent can be used to predict the clinical result and elucidate the possible mechanism of action of espb.

Eligibility criteria:
inclusion criteria: * cervical facet joint arthrosis * cervical foraminal stenosis * cervical herniated intervertebral disc * myofascial pain syndrome of upper back muscle exclusion criteria: * allergy to local anesthetics or contrast medium * pregnancy * prior history of cervical spine surgery * coagulation abnormality

Keywords: pain, cervical, spread
evaluation of the cost and effectiveness sunitinib compared to interferon-alfa in finland

Conditions: Neoplasms; Renal Cell Carcinoma

Summary: patient receiving sunitinib according the clinician's independent decision as first-line treatment of advanced renal cell carcinoma (rcc) will be asked for informed consent. treatment with sunitinib will start and end solely on the treating clinicians and the patients independent discretion. consenting patients will prospectively answer standardized quality of life questionnaires (15d, eq-5d) during the treatment. data on health care resource utilisation will be collected prospectively (outpatient visits, hospital stays, concomitant drugs, investigations, sick-leaves, travels). in addition, after treatment failure anti-cancer drugs, hospital stays and date of death will be recorded. the health economic data during sunitinib treatment and the length of the sunitinib treatment will be compared with the corresponding previously published data collected retrospectively from patients with the same condition treated with ifn-alfa. stepwise regression analysis will be used to explore whether patient and tumor characteristics explain potential variation in treatment duration and costs that is not explained by the treatment. health-related quality of life (hrqol) data will be presented as descriptive data and compared to age-standardized general population. at least four major finnish oncology centers have consented to participate in this study. the inclusion time will be approximately 24 months, and the study time approximately 48 months. eighty patients will be included.


Eligibility criteria:
inclusion criteria: * clinically indicated first-line sunitinib treatment for advanced rcc. * informed consent obtained. exclusion criteria: * unable to complete hrqol forms. * not consenting to collecting register data.

Keywords: renal cell cancer sunitinib costs quality of life
study for safety and efficacy evaluation of imatinib mesylate in children with acute lymphoblastic leukemia (all) philadelphia chromosome-positive (ph+)

Conditions: Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+)

Summary: the purpose of this study is to evaluate the efficacy, through molecular response and event-free survival, about the use of imatinib in conjunction with chemotherapy after bfm "like" induction in children with all ph+.


Eligibility criteria:
inclusion criteria: 1. diagnose: therapy-naïve all, except for patients that performed induction for all (33 days) exactly as this protocol and; documented ph+, to be confirmed by conventional cytogenetic - t(9;22) (q34;q11) or fish and/or gene bcr-abl presence by rt-pcr or fish. 2. female patients of childbearing age, should have pregnancy test (blood βhcg) performed before treatment initiation. effective contraception must be used during treatment. pregnant women won't be included. 3. life expectation \> 8 weeks. 4. medications: antineoplastic treatment-naïve, including corticotherapy, except for patients that performed induction for all (33 days) exactly as this protocol. 5. signed icf by child legal responsible. 6. laboratory: renal function (serum creatinine ≤ 1,5 x uln and/or clearance ≥70 ml/min/1,73m2), hepatic function (total bilirubin ≤ 1,5 x uln, tgp/tgo \ 2 g/dl. exclusion criteria: 1. any inclusion criteria missing. 2. pregnant patient or breastfeeding. 3. patient considered incapable to follow purposed treatment. 4. subject with infectious process, in activity, grade iv.
biomarker for maroteaux-lamy disease (biomaroteaux)

Conditions: Lysosomal Storage Disease; Lung Diseases; Obstructive Sleep Apnoea; Macroglossia; Eye Abnormalities

Summary: development of a new ms-based biomarker for the early and sensitive diagnosis of maroteaux-lamy disease from blood

maroteaux-lamy disease (mps vi) is a lysosomal storage disease inherited in an autosomal recessive pattern. the responsible mutations lie in arsb (5q11-q13), the gene that encodes the enzyme arylsulfatase b. the phenotype results from defective dermatan sulfate break-down with lysosomal accumulation. this accumulation of glycosaminoglycans is responsible for the widespread signs and symptoms found in this disease. bone destruction in shoulders, hips and skull is often seen by the second decade of life and may become evident later in the knees and spine. early growth may be normal but eventually slows resulting in short stature. dysplasia of bones comprising these joints leads to stiffness and restricted movement. the face is dysmorphic with coarse features. bone dysplasia and facial dysmorphism may be seen at birth. myelopathy and even tetraplegia can result from vertebral compression. intelligence is often normal although more severely affected individuals may have some cognitive defects due to impaired vision and hearing. hepatosplenomegaly is common and compromised respiratory function can result in reduced physical stamina. the tongue is usually enlarged. accumulation of dermatan sulfate in heart valves may produce insufficiency or restriction of outflow. a diagnosis of maroteaux-lamy disease can be confirmed by screening for the common genetic mutations or measuring the level of the arylsulfatase b enzyme activity in a blood sample -- a test that has 100 percent accuracy. once maroteaux-lamy disease is diagnosed, testing of all family members and consultation with a professional geneticist is recommended. carriers are most reliably identified via genetic mutation analysis. new methods, like mass-spectrometry give a good chance to characterize in the blood (plasma) of affected patents specific metabolic alterations that allow to diagnose in the future the disease earlier, with a higher sensitivity and specificity. therefore it is the goal of the study to develop new biochemical markers from the plasma of the affected patients helping to benefit the patient by an early diagnose and thereby with an earlier treatment.

Eligibility criteria:
inclusion criteria: * informed consent will be obtained from the patient or the parents before any study related procedures. * patients older than 12 months * the patient has a diagnosis of maroteaux-lamy disease exclusion criteria: * no informed consent from the patient or the parents before any study related procedures * patients younger than 12 months * the patient has no diagnosis of maroteaux-lamy disease

Keywords: maroteaux-lamy disease biomarker
development of magnetic resonance spectroscopy (mrs) biomarkers of tumor metabolism (mk-0000-145)

Conditions: Glioma

Summary: this study will evaluate the test-retest repeatability of lactate and other metabolites measured by single voxel magnetic resonance spectroscopy (mrs) and multi-voxel magnetic resonance spectroscopic imaging experiments (mrsi) in tumor tissue in patients radiographically diagnosed with glioma. these measurements will test whether the concentration of lactate in tumor will be higher than the concentration of lactate in normal tissue of the same patient.


Eligibility criteria:
inclusion criteria: * male and female patients aged 18-70 years old with newly diagnosed operable glioma of grade ii or higher which is \> 3cm in diameter based on radiographic examination * patients about to receive biopsy or resection of newly diagnosed glioma exclusion criteria: * contraindication to magnetic resonance imaging (mri): e.g. cardiac pacemaker, metallic implants, known contrast allergy, and pregnancy * impaired renal function * current or previous chemotherapy, radiation, or other tumor treatment excluding steroids * tumor location extra-cerebral, temporal, or in close proximity to frontal sinus

Keywords: magnetic resonance spectroscopy (mrs) lactate editing metabolite content glioma
comparison of amcop bioactivator and high-pull headgear in treating skeletal class ii hyperdivergent pediatric patients

Conditions: Skeletal Malocclusion

Summary: the aim of the present study was to retrospectively compare the clinical use of high-pull headgear versus amcop bioactivators for hyperdivergent pediatric patients. cephalometric radiographs from pediatric patients treated at the unit of orthodontics and pediatric dentistry, section of dentistry, department of clinical, surgical, diagnostic and pediatric sciences, university of pavia, pavia, italy and at the private practice of dr. cardarelli, isernia, italy will be collected. cephalometric tracing from giannì analysis will be performed at the baseline (t0) and after 18 months of treatment (t1).

the aim of the present study was to retrospectively compare the clinical use of high-pull headgear versus amcop bioactivators for hyperdivergent pediatric patients. cephalometric radiographs from pediatric patients treated at the unit of orthodontics and pediatric dentistry, section of dentistry, department of clinical, surgical, diagnostic and pediatric sciences, university of pavia, pavia, italy and at the private practice of dr. cardarelli, isernia, italy will be collected. cephalometric tracing from giannì analysis will be performed at the baseline (t0) and after 18 months of treatment (t1).

Eligibility criteria:
inclusion criteria: * mixed or permanent dentition * skeletal class ii malocclusion diagnosed with anb angle \> 4° from cephalometric radiograph * skeletal hyperdivergency calculated from anspns\^gogn angle \> 25°, and at least s-ar\^go \> 149° or ar-go\^gn \> 137° exclusion criteria: * lack of compliance in the use of the orthodontic appliance * syndromic patients, cleft lip or cleft palate, severe malformations and asymmetries of the jaws.

Keywords: hyperdivergency
intensity modulated radiation therapy - prostate cancer

Conditions: Prostatic Neoplasms

Summary: there are several different treatment schedules being used across the world for treatment of prostate cancer with radiation therapy. in order to determine the best radiation treatment for this disease, a study is being performed by the doctors at the princess margaret hospital. this study will try to measure the effectiveness and side effects of an increased dose of radiation to the prostate that is also given over a shorter number of weeks than is usually done. in order to try to reduce the possible side effects of the radiation therapy the treatment will be given using special techniques to shield as much of your normal body tissues as possible. this method of treatment is called conformal intensity modulated radiation therapy, or imrt.


Eligibility criteria:
inclusion criteria: * histologic diagnosis of adenocarcinoma of the prostate within six months of entry * clinical stage t1b, t1c, t2a-c nx mo (see appendix 1 for staging). any gleason score is eligible for entry, but gleason score must be determined. * patients with a psa \>10.0 and gleason score of 7; or patients with any psa value and gleason score of \>8 must have clinically negative lymph nodes as determined by a pelvic ct scan done within 12 weeks of entry. a negative bone scan is required before entry for all patients with gleason score \>8, or any patient with a gleason score of 7, and a psa \>10. * the patient must not have received any cytotoxic anticancer therapy. previous or concurrent hormonal therapy for local disease is acceptable. * ecog performance status of 1 or less * age 80 years old or less * serum psa \<25 ng/ml within 4 weeks of study entry * informed consent exclusion criteria: * patients with history of inflammatory bowel disease or other contraindication to radical radiation therapy * patients with prior colorectal surgery * any prior pelvic radiotherapy. any prior turp done \<12 weeks from study entry. * any previous cytotoxic chemotherapy * patients with prior malignancy except non-melanoma skin carcinoma within 5 years of the diagnosis of prostate cancer
long-term safety and tolerability of degarelix one-month dosing regimen in korean patients

Conditions: Prostate Cancer

Summary: this is an open-label, multi-centre single arm trial to investigate long-term safety and tolerability of degarelix in korean patients with prostate cancer.


Eligibility criteria:
inclusion criteria: * has given written informed consent before any trial-related activity is performed. a trial-related activity is defined as any procedure that would not have been performed during the normal management of the patient * has completed the 7-month main trial, fe200486 cs42 exclusion criteria: * has been withdrawn/discontinued from the fe200486 cs42 trial * a patient may also not be entered into the cs42a trial at the discretion of the investigator due to safety or lack of efficacy concerns (lh or psa response) in the cs42 trial.
data collection study of raw thermal images for the purpose of developing a device for early detection of breast cancer

Conditions: Breast Cancer

Summary: collection of thermal "images" of women with breast tumors in varying degrees of severity and of healthy women with no breast findings, in order to evaluate and improve real imaging's device ("ri4.0"), capabilities which will assist in early detection of breast cancer.


Eligibility criteria:
inclusion criteria: * gender: female * age: 18 years and older * subjects with a breast abnormality (identified by mammography, ultrasound, mri and/or a clinical examination) summoned for breast biopsy or subjects summoned for a routine screening examination. * subject who have signed an informed consent form. exclusion criteria: * subjects who have had a mammography, ultrasound, and/or mri examination performed on the day of the study, prior to being "imaged" by ri4.0. * subjects who have undergone any type of breast surgery throughout the 6 weeks preceding the study. * subjects who have had a breast biopsy performed throughout the 6 weeks preceding the study. * subjects who have undergone a mastectomy. * subjects who have a large scar (causing breast deformation) following breast lumpectomy and/or any other cause (e.g. accident). * subjects with prior breast reduction surgery or breast augmentation surgery. * subjects who have a fever on the day of their biopsy. * subjects who are pregnant. * subjects who are breast-feeding.
study of phenobarbital inhibition of catamenial epilepsy

Conditions: Epilepsy

Summary: the purpose of this study is to test the effectiveness of low-dose phenobarbital on the treatment of catamenial epilepsy. we propose that since the catamenial seizures are associated with the reduction in levels of gaba-enhancing allopregnanolone, short-term replacement with the gabar-enhancing agent phenobarbital will reduce the incidence of catamenial seizures.


Eligibility criteria:
inclusion criteria: * adult female patients seeking medical attention for seizures * regular menstrual cycles * at least 2 seizures per month * must be on at least one form of birth control other than abstinence * must be on a stable anticonvulsant regimen of at least one and not exceeding three anticonvulsants, and not be using any perimenstrual seizure medications of hormone preparations * if taking benzodiazepines for therapeutic purposes, must be on a stable regular dose * must be willing to take at least 400mcg of folic acid a day while in the study * must be able to detect, count or record seizures exclusion criteria: * can not be pregnant or trying to become pregnant * can not have used hormonal birth control methods for at least 3 months prior to enrollment * can not have an allergy to phenobarbital * can not have a history of non-epileptic seizures * can not have a know liver dysfunction or history of chronic hepatitis * can not have a history of neurological disorder or history of status epilepticus in the preceding year * can not ahve a physical or psychiatric condition which in the pis opinion could compromise her ability to participate
impact of thn102 on attention, wakefulness and cognitive performance during total sleep deprivation

Conditions: Sleep Deprivation

Summary: study objectives: thn102 is a new combination between modafinil and flecainide low-dose, a documented glial connexin inhibitor. efficacy of thn102 was compared to modafinil and to placebo on parameters impaired by total sleep deprivation (sd, lasting 40h). methods: 20 healthy male subjects participated in a double-blind, randomised, incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo (pbo), modafinil 100 mg (mod), and combinations thn102 (modafinil 100 mg and 1, 3 or 9 mg flecainide as thn1, thn3 and thn9), as 3 oral doses over 18h.


Eligibility criteria:
main inclusion criteria: 1. male subjects considered healthy and aged between 18 and 40 years 2. subject with a body mass index (bmi) between 18 and 30 kg/m2

Keywords: modafinil connexin sleep deprivation cognitive performance
cost effectiveness and utility of computed tomography angiography (cta) and cardiac cath

Conditions: Heart Diseases

Summary: this is a research study to determine patient preferences between two different diagnostic tests; a ct angiogram (cta) and a catheter angiogram, both of which are used at the university to screen for and detect heart disease.

this is a single site study that will retrospectively and prospectively identify and enroll 100 subjects, both male and female, 18 years of age and older who undergo both coronary angiography and coronary artery computed tomography (ct), using the electronic radiology and cardiology databases. the purpose is to conduct a survey to assess their preference for either test to diagnose coronary artery disease. subjects should be within six months of having the tests to avoid memory and recall problems.

Eligibility criteria:
inclusion criteria: * subjects who have had both cta and coronary angiogram. * 18 years old and older. exclusion criteria: * under 18 years of age * memory impairment: * stroke * traumatic brain injury * dementia
20-valent pneumococcal conjugate vaccine safety study in healthy infants

Conditions: Pneumococcal Disease

Summary: this study is designed to evaluate the safety and tolerability of 20vpnc in healthy infants.


Eligibility criteria:
inclusion criteria: * male or female infants born at ≥34 weeks of gestation and who are 2 months of age (≥42 to ≤98 days) at the time of consent (the day of birth is considered day of life 1). * healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study. exclusion criteria: * previous vaccination with any licensed or investigational pneumococcal vaccine, or planned receipt through study participation. * major known congenital malformation or serious chronic disorder.
middle meningeal artery embolization for chronic subdural hematoma

Conditions: Chronic Subdural Hematoma

Summary: endovascular middle meningeal artery (mma) embolization is an emerging treatment for chronic subdural hematoma (csdh). there is preliminary data to suggest that this minimally invasive therapy may be more efficacious and equally as safe compared to conventional, more invasive surgery. this study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma as an adjunct to standard treatments, which include medical management and surgical evacuation.

this study seeks to assess the safety and efficacy of middle meningeal artery embolization for chronic subdural hematoma in addition to standard treatments, which include close observation and surgical evacuation. middle meningeal artery embolization has emerged recently as a minimally invasive and successful method of preventing re-accumulation of subdural hematoma, particularly for patients that are not obvious surgical candidates or those with recurrent or refractory hematomas. the outcomes of these two groups of patients who undergo middle meningeal artery embolization will be compared to matched historical controls. middle meningeal artery embolization is a minimally invasive angiography procedure completed with use of fluoroscopy. access is obtained through the femoral or radial artery and a catheter is advanced to the mma. polyvinyl alcohol particles are then injected to seal off this portion of the artery and prevent any further blood flow into the subdural hematoma. hemostasis is obtained at the access site and the patient is observed for 24-48 hours on a neurological care unit before discharge. a head ct, nihss, and modified rankin score will be repeated on the following schedule: • pre-procedure * 24 hours post procedure * 7-10 days post procedure * 30 days post procedure * 90 days post procedure patients with chronic subdural hematoma undergo ct scans and neurologic assessments on hospital admission, as well as follow up ct scans and neurologic assessments to assess for any change in neurologic status or hematoma size. this study utilizes a standard of care follow up schedule to avoid exposing participants to extra radiation. participants will be followed for study related purposes for 90 days.

Eligibility criteria:
inclusion criteria: * patients 18 years or older undergoing treatment for a new diagnosis of chronic subdural hematoma (csdh) or * patients 18 year or older who have undergone surgical evacuation of a subdural hematoma and have a significant residual hematoma status post-surgery or who develop a recurrent subdural hematoma. and * minimal symptoms such as headache, altered mental status, or mild neurological deficit only * ability to understand and sign written informed consent by patient or lar exclusion criteria: * significant midline shift and/or neurologic symptoms requiring urgent decompression. * common carotid stenosis of over 50%. * significant contraindication to angiography (eg. kidney failure, difficult anatomy). * sdh related to underlying condition * acute sdh